Generic Rozerem Availability
ROZEREM (ramelteon - tablet; oral)
Manufacturer: TAKEDA PHARMS USA
Approval date: July 22, 2005
Strength(s): 8MG [RLD]
Has a generic version of Rozerem been approved?
No. There is currently no therapeutically equivalent version of Rozerem available.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Rozerem. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Tricyclic compounds, their production and use
Issued: March 7, 2000
Inventor(s): Ohkawa; Shigenori & Uchikawa; Osamu & Fukatsu; Kohji & Miyamoto; Masaomi
Assignee(s): Takeda Chemical Industries, Ltd.
A compound of the formula: ##STR1## wherein R.sup.1 is an optionally substituted hydrocarbon, amino or heterocyclic group; R.sup.2 is H or an optionally substituted hydrocarbon group; R.sup.3 is H or an optionally substituted hydrocarbon or heterocyclic group; X is CHR.sup.4, NR.sup.4, O or S in which R.sup.4 is H or an optionally substituted hydrocarbon group; Y is C, CH or N; ring A is optionally substituted 5- to 7-membered ring; ring B is an optionally substituted benzene ring; and m is 1 to 4, or a salt thereof, a process for producing it, an intermediate for the production and a pharmaceutical composition comprising it are provided.Patent expiration dates:
- July 22, 2019✓✓✓
- July 22, 2019
- Rozerem Consumer Information (Drugs.com)
- Rozerem Consumer Information (Wolters Kluwer)
- Rozerem Consumer Information (Cerner Multum)
- Rozerem Advanced Consumer Information (Micromedex)
- Rozerem AHFS DI Monographs (ASHP)
- Ramelteon Consumer Information (Wolters Kluwer)
- Ramelteon Consumer Information (Cerner Multum)
- Ramelteon Advanced Consumer Information (Micromedex)
- Ramelteon AHFS DI Monographs (ASHP)
|Drug Patent||A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.|
|Drug Exclusivity||Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.|
|RLD||A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.|